Ralaniten

Research use only, not for human use.

Ralaniten (EPI-506) is a novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer.

Ralaniten (EPI-506) is a novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer; AR NTD-targeting agents have the potential to overcome shortcomings of current hormonal therapies by inhibiting all forms of AR-mediated transcriptional activity, and as a result, may affect a broader AR population including mutational and splice variant ARs.Prostate Cancer Phase 2 Clinical.

——

Animal Model:Male NOD-SCID mice bearing subcutaneous tumors were castratedDosage:100 mg/kg Administration:P.o. twice daily for 28 days Result:Inhibited the growth of castration-resistant prostate cancer (CRPC) xenografts that express AR splice variants.

EPI-506

Endocrinology/Hormones

Estrogen Receptor/ERR

Estrogen Receptor/ERR

Cancer

Prostate Cancer

1203490-23-6

394.89

C21H27ClO5

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (253.24 mM)

CC(C)(C1=CC=C(C=C1)OCC(CO)O)C2=CC=C(C=C2)OCC(CCl)O

(2R)-3-[4-(2-{4-[(2S)-3-chloro- 2-hydroxypropoxy]phenyl}propan-2-yl)phenoxy]propane- 1,2-diol

(-20℃)

With Ice Pack

≥ 2 years